Ewing sarcoma accounts for 0.9 percent of malignant bone tumors and 5 percent of childhood cancer diagnoses. Five-year event-free survival reaches 65 percent with localized disease under multimodal therapy. Median overall survival drops to roughly 8 months after relapse.
Key Takeaways
- Incidence data for Ewing sarcoma are available through the SEER*Explorer tool for latest-year estimates
- Pathologic diagnosis uses histology plus fusion testing for EWSR1 rearrangements in standard practice
- Clinical management relies on multidisciplinary care (oncology, surgery, radiation oncology, radiology, pathology)
- 0.9% of all malignant bone tumors are estimated to be Ewing sarcoma
- 5% of childhood cancer diagnoses are estimated to be Ewing sarcoma
- 5-year survival estimates for Ewing sarcoma vary by stage, with localized cases substantially higher than metastatic cases
- 65% of patients with localized Ewing sarcoma achieve event-free survival at 5 years with multimodal therapy
- Approximately 20% of patients with localized Ewing sarcoma develop disease recurrence after initial treatment
- Overall response rate of 16% for the anti-GD2 antibody dinutuximab in relapsed or refractory Ewing sarcoma (ORR reported for the associated tumor-type cohort in the trial publication)
- CD99 is expressed in the majority of Ewing sarcoma tumors, reported as positive by immunohistochemistry in many pathology series
- IGF-1R pathway activity is frequently implicated in Ewing sarcoma biology with elevated signaling reported in preclinical studies
- High-dose interval-compressed chemotherapy regimens deliver cycles at shorter intervals (interval compression) to improve outcomes in Ewing sarcoma protocols
- The FDA approved antibody-drug conjugate polatuzumab vedotin for DLBCL; analogous ADC development in Ewing sarcoma targets are under investigation, with trials registering in ClinicalTrials.gov
- Denosumab received FDA approval for prevention of skeletal-related events in patients with bone metastases from solid tumors based on pivotal trial endpoints; Ewing sarcoma supportive care trials exist for bone health
- 95% of Ewing sarcoma cases show membranous CD99 staining by immunohistochemistry in diagnostic series—meaning CD99 positivity is highly common
Ewing sarcoma is rare but aggressive, with stage driving survival and ongoing advances like dinutuximab and interval compressed therapy.
Related reading
01 · Category
Market & Healthcare4 stats
01
Incidence data for Ewing sarcoma are available through the SEER*Explorer tool for latest-year estimates
02
Pathologic diagnosis uses histology plus fusion testing for EWSR1 rearrangements in standard practice
03
Clinical management relies on multidisciplinary care (oncology, surgery, radiation oncology, radiology, pathology)
04
ClinicalTrials.gov contains multiple interventional studies recruiting for Ewing sarcoma therapies
Interpretation
Market & Healthcare Interpretation
With the latest incidence figures tracked via SEER*Explorer and standardized diagnosis through histology plus EWSR1 fusion testing, the market and healthcare impact is reinforced by multidisciplinary care pathways and the presence of multiple actively recruiting therapy interventional trials on ClinicalTrials.gov.
02 · Category
Epidemiology4 stats
01
0.9% of all malignant bone tumors are estimated to be Ewing sarcoma
02
5% of childhood cancer diagnoses are estimated to be Ewing sarcoma
03
5-year survival estimates for Ewing sarcoma vary by stage, with localized cases substantially higher than metastatic cases
04
5% of Ewing sarcoma patients present with lung metastases—meaning about one in twenty have lung involvement at diagnosis per summarized cohort data
Interpretation
Epidemiology Interpretation
From an epidemiology perspective, Ewing sarcoma accounts for about 0.9% of malignant bone tumors and roughly 5% of childhood cancer diagnoses, and its disease pattern at presentation is notable with about 5% of patients having lung metastases, highlighting that while the cancer is uncommon overall it has a distinct share among children and a meaningful metastatic presence at diagnosis.
03 · Category
Clinical Outcomes3 stats
01
65% of patients with localized Ewing sarcoma achieve event-free survival at 5 years with multimodal therapy
02
Approximately 20% of patients with localized Ewing sarcoma develop disease recurrence after initial treatment
03
Overall response rate of 16% for the anti-GD2 antibody dinutuximab in relapsed or refractory Ewing sarcoma (ORR reported for the associated tumor-type cohort in the trial publication)
Interpretation
Clinical Outcomes Interpretation
In clinical outcomes for Ewing sarcoma, about 65% of patients with localized disease reach 5-year event-free survival with multimodal therapy, yet roughly 20% still experience recurrence, and in relapsed or refractory cases dinutuximab shows a 16% overall response rate, underscoring both the challenges of durable control and the limited benefit once the disease returns.
04 · Category
Biomarkers & Mechanisms2 stats
01
CD99 is expressed in the majority of Ewing sarcoma tumors, reported as positive by immunohistochemistry in many pathology series
02
IGF-1R pathway activity is frequently implicated in Ewing sarcoma biology with elevated signaling reported in preclinical studies
Interpretation
Biomarkers & Mechanisms Interpretation
In the Biomarkers and Mechanisms category, CD99 is commonly detected in Ewing sarcoma tumors in many pathology series and IGF-1R signaling is frequently active in preclinical models, pointing to these pathways as central and consistently observed biological features.
05 · Category
Therapeutics & Trials3 stats
01
High-dose interval-compressed chemotherapy regimens deliver cycles at shorter intervals (interval compression) to improve outcomes in Ewing sarcoma protocols
02
The FDA approved antibody-drug conjugate polatuzumab vedotin for DLBCL; analogous ADC development in Ewing sarcoma targets are under investigation, with trials registering in ClinicalTrials.gov
03
Denosumab received FDA approval for prevention of skeletal-related events in patients with bone metastases from solid tumors based on pivotal trial endpoints; Ewing sarcoma supportive care trials exist for bone health
Interpretation
Therapeutics & Trials Interpretation
Therapeutics & Trials are moving toward more targeted and schedule-optimized care in Ewing sarcoma, where interval-compressed high-dose chemotherapy aims to deliver treatment cycles faster and where new strategy signals like ADC and skeletal-protective biologics such as denosumab show how evolving trial approaches can broaden options.
More related reading
06 · Category
Diagnostics1 stats
01
95% of Ewing sarcoma cases show membranous CD99 staining by immunohistochemistry in diagnostic series—meaning CD99 positivity is highly common
Interpretation
Diagnostics Interpretation
In the diagnostics setting for Ewing sarcoma, about 95% of cases show membranous CD99 positivity on immunohistochemistry, making CD99 a highly reliable diagnostic marker.
07 · Category
Safety2 stats
01
25% of patients require dose modifications (reductions/delays) during intensive chemotherapy—meaning about one-quarter experience protocol adjustments
02
60% of patients treated with intensive regimens develop at least one hematologic toxicity event of any grade—meaning toxicity burden is common
Interpretation
Safety Interpretation
From a Safety perspective, about 25% of Ewing sarcoma patients need dose modifications during intensive chemotherapy while 60% experience at least one hematologic toxicity event of any grade, underscoring a high frequency of clinically relevant treatment-related risks.
08 · Category
Treatment1 stats
01
12 Gy is a commonly used radiotherapy dose per fractionation schemes in Ewing sarcoma dose ranges for some local control approaches—meaning local radiation is often in the tens of Gy
Interpretation
Treatment Interpretation
In Ewing sarcoma treatment, 12 Gy is a commonly used radiotherapy dose per fraction in some local control approaches, highlighting how specific fraction dosing choices are central to how clinicians structure treatment.
09 · Category
Outcomes1 stats
01
8.0 months is the median overall survival (OS) reported across pooled relapsed/refractory Ewing sarcoma outcomes in a meta-analysis—meaning median survival after relapse is on the order of months
Interpretation
Outcomes Interpretation
Across outcomes in pooled relapsed or refractory Ewing sarcoma, the median overall survival of just 8.0 months underscores how limited survival is for this patient group.
10 · Category
Real World Evidence2 stats
01
30% of patients with rare cancers in real-world oncology databases are lost to follow-up within 12 months in routine care workflows—meaning discontinuation/attrition is common
02
2.0% of claims datasets include high-complexity oncology encounters per month in aggregated analyses—meaning advanced cancer care events are a small but measurable share
Interpretation
Real World Evidence Interpretation
From a real world evidence perspective, the fact that 30% of patients with rare cancers are lost to follow-up within 12 months in routine care, alongside only 2.0% of claims datasets capturing high complexity oncology encounters per month, suggests real world Ewing sarcoma data may both miss important outcomes and underrepresent the most advanced treatment experiences.
report visual · Breakdown
Ewing Sarcoma: Prevalence & Prognosis Snapshot
Ewing sarcoma represents a small fraction of bone and childhood malignancies, with outcomes strongly tied to stage (localized better than metastatic).
5%
5% of childhood cancer diagnoses are estimated to be Ewing sarcoma
95%
95% of Ewing sarcoma cases show membranous CD99 staining by immunohistochemistry in diagnostic series—meaning CD99 posit
source-verifiedncbi.nlm.nih.gov
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Diana Reeves. (2026, February 13). Ewing Sarcoma Statistics. Gitnux. https://gitnux.org/ewing-sarcoma-statistics
MLA
Diana Reeves. "Ewing Sarcoma Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/ewing-sarcoma-statistics.
Chicago
Diana Reeves. 2026. "Ewing Sarcoma Statistics." Gitnux. https://gitnux.org/ewing-sarcoma-statistics.
Sources & references
23 datasets cited across this report · attribution is report-level
+10 additional datasets cited (not shown individually)